Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

NCT01980654 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT01980654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01980654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2013
Completion date
November 30, 2017
Enrollment
80 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, follicular lymphoma, non-hodgkin's lymphoma